17-Jul-2026
As Q2 earnings kick off, these small-cap stocks earn an A+ for profitability
Seeking Alpha News (Fri, 17-Jul 1:06 PM ET)
Globe Newswire (Tue, 23-Jun 7:30 AM ET)
Zevra's Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition
Globe Newswire (Thu, 11-Jun 8:30 AM ET)
Zevra Secures Extended Patent Protection for MIPLYFFA, Solidifying Market Exclusivity to 2041
Market Chameleon (Tue, 9-Jun 6:32 AM ET)
Globe Newswire (Mon, 8-Jun 7:30 AM ET)
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 29-May 4:30 PM ET)
Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference
Globe Newswire (Tue, 12-May 7:30 AM ET)
Zevra Reports First Quarter 2026 Financial Results and Corporate Update
Globe Newswire (Wed, 6-May 4:05 PM ET)
Zevra Therapeutics Announces Details for Q1 2026 Financial Results Call
Globe Newswire (Wed, 22-Apr 7:30 AM ET)
Zevra’s 2025 Financials Signal Turnaround as MIPLYFFA Drives Rare Disease Momentum
Market Chameleon (Tue, 10-Mar 5:53 AM ET)
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
Zevra Therapeutics trades on the NASDAQ stock market under the symbol ZVRA.
As of July 17, 2026, ZVRA stock price climbed to $12.77 with 612,343 million shares trading.
ZVRA has a beta of 0.61, meaning it tends to be less sensitive to market movements. ZVRA has a correlation of 0.01 to the broad based SPY ETF.
ZVRA has a market cap of $754.90 million. This is considered a Small Cap stock.
Last quarter Zevra Therapeutics reported $36 million in Revenue and $.18 earnings per share. This beat revenue expectation by $4 million and exceeded earnings estimates by $.10.
In the last 3 years, ZVRA traded as high as $15.04 and as low as $3.89.
The top ETF exchange traded funds that ZVRA belongs to (by Net Assets): VTI, IWM, VXF, JSMD, IBB.
ZVRA has underperformed the market in the last year with a price return of +0.9% while the SPY ETF gained +19.5%. However, in the short term, ZVRA had mixed performance relative to the market. It has outperformed in the last 3 months, returning +19.7% vs +4.9% return in SPY. But in the last 2 weeks, ZVRA shares have been beat by the market, returning -8.7% compared to an SPY return of -0.2%.
ZVRA support price is $12.39 and resistance is $13.13 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ZVRA shares will trade within this expected range on the day.